Supernus Pharm (SUPN) Stock Price, Quote & News

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 838 2500

Website: www.supernus.com

Address:

9715 Key West Avenue, Rockville, United States

Iightning Dec. 5 at 4:23 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $46C Entry: 1.02 Exit: 1.83 Return: +79.02% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 10:10 PM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $46C Entry: 1.02 Exit: 1.83 Return: +79.02% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 5:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $46C Entry: 1.55 Exit: 1.89 Return: +21.77% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 9:48 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $42C Entry: 6.30 Exit: 8.42 Return: +33.61% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:15 PM

$SUIG $SUPN $SUPV $SVRA $SWKS proven Accuracy

0 · Reply

Iightning Dec. 2 at 12:06 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $SUPN **Contract:** Dec 19 $45C **Entry:** 2.28 **Exit:** 3.76 **Return:** **+65.03% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Iightning Nov. 26 at 2:57 AM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $46 Call | Enter: $1.98 Exit: $2.85 | Profit: 44.47% ROI | https://1ightning.com

0 · Reply

iamyahweh Nov. 25 at 3:46 PM

$SUPN 🚀🚀🚀🚀🚀🚀

0 · Reply

Iightning Nov. 25 at 1:01 PM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $46 Call | Enter: $1.98 Exit: $2.85 | Profit: 44.47% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:56 AM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $46 Call | Enter: $1.98 Exit: $2.85 | Profit: 44.47% ROI | https://1ightning.com

0 · Reply

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

Nov 21, 2025, 4:06 PM EST - 13 days ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 4:05 PM EST - 22 days ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Nov 5, 2025, 12:36 AM EST - 4 weeks ago

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Supernus Announces Third Quarter 2025 Financial Results

Oct 21, 2025, 5:00 PM EDT - 6 weeks ago

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Sep 17, 2025, 4:05 PM EDT - 2 months ago

Supernus Pharmaceuticals: Heading In The Right Direction

Aug 27, 2025, 4:15 PM EDT - 3 months ago

Supernus Pharmaceuticals to Participate in September Investor Conferences

Aug 5, 2025, 6:18 PM EDT - 4 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 4 months ago

Supernus Announces Second Quarter 2025 Financial Results

Jul 31, 2025, 8:44 AM EDT - 4 months ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Jul 28, 2025, 8:25 AM EDT - 4 months ago

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Jul 22, 2025, 4:30 PM EDT - 4 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

Jul 14, 2025, 4:25 PM EDT - 5 months ago

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SAGE

Jun 16, 2025, 5:31 PM EDT - 6 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

SAGE

Jun 16, 2025, 7:14 AM EDT - 6 months ago

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

SAGE

Jun 16, 2025, 7:00 AM EDT - 6 months ago

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

May 29, 2025, 8:30 AM EDT - 6 months ago

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 28, 2025, 4:05 PM EDT - 6 months ago

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025, 4:05 PM EDT - 6 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 10:55 PM EDT - 7 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:08 PM EDT - 7 months ago

Supernus Announces First Quarter 2025 Financial Results

Apr 23, 2025, 5:14 PM EDT - 8 months ago

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

Iightning Dec. 5 at 4:23 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $46C Entry: 1.02 Exit: 1.83 Return: +79.02% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 10:10 PM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $46C Entry: 1.02 Exit: 1.83 Return: +79.02% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 5:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $46C Entry: 1.55 Exit: 1.89 Return: +21.77% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 9:48 AM

1ightning® Premium Options Alert (Actionable) Ticker: $SUPN Contract: Dec 19 $42C Entry: 6.30 Exit: 8.42 Return: +33.61% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:15 PM

$SUIG $SUPN $SUPV $SVRA $SWKS proven Accuracy

0 · Reply

Iightning Dec. 2 at 12:06 AM

0 · Reply

Iightning Nov. 26 at 2:57 AM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $46 Call | Enter: $1.98 Exit: $2.85 | Profit: 44.47% ROI | https://1ightning.com

0 · Reply

iamyahweh Nov. 25 at 3:46 PM

$SUPN 🚀🚀🚀🚀🚀🚀

0 · Reply

Iightning Nov. 25 at 1:01 PM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $46 Call | Enter: $1.98 Exit: $2.85 | Profit: 44.47% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:56 AM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $46 Call | Enter: $1.98 Exit: $2.85 | Profit: 44.47% ROI | https://1ightning.com

0 · Reply

BEATOFtheMARKET Nov. 23 at 5:46 PM

$SUIG $SUPN $SUPV $SVRA $SWKS 🔥

0 · Reply

Iightning Nov. 21 at 11:13 PM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $45 Call | Enter: $2.78 Exit: $4.48 | Profit: 61.38% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 2:30 AM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $45 Call | Enter: $2.78 Exit: $4.48 | Profit: 61.38% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 11:55 PM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $45 Call | Enter: $2.78 Exit: $4.48 | Profit: 61.38% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:10 AM

1ightning® Options Trade Alert (Actionable) | Buy $SUPN Dec 19 $45 Call | Enter: $2.78 Exit: $4.48 | Profit: 61.38% ROI | https://1ightning.com

0 · Reply

nikitatrades Nov. 16 at 12:27 PM

🚀 $SUPN Token (Superp) Analysis! 🚀 ✨ Innovative Trading: SUP fuels Superp, a DEX offering "No Liquidation" high-leverage trading for volatile assets like meme coins. Imagine a trading safety net, reducing abrupt losses! 🗳️ Community Power: Holding SUP gives you a voice in platform governance, letting you shape its future like a shareholder, plus staking rewards. 📈 Growing Ecosystem: With $37B+ volume (Q3 2025), and plans for Solana expansion, Superp is expanding its reach. ⚠️ Supply Dynamics: A large portion of SUP's 1B tokens are still locked, so future unlocks could create selling pressure. #Crypto #DeFi #Superp

0 · Reply

SuperGreenToday Nov. 11 at 8:56 PM

$SUPN Share Price: $46.14 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.39 – $4.14 Potential Upside: 51% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

fullobullz Nov. 7 at 8:19 PM

$CING Anyone else think $80 may actually be in line if they get PUFDA or im I just an idiot? $CING already has patents in these countries: Australia, Canada, Israel, and Europe. Add pending US, Korea and Hong Kong and your looking at a nice market share lock. $SUPN $AXSM have mc over $1B and I think $CING could hit that as well once given pufda. Interested to hear everyone's thoughts for long term

2 · Reply

d_risk Nov. 7 at 12:54 AM

$SUPN - Supernus Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors SUPN updates tariff risk to focus on newly announced tariffs for pharmaceuticals, drops risks tied to 2025 drug pricing Executive Orders, and adds new warnings about costly, distracting legal actions. #Pharmaceuticals #RegulatoryChanges #LegalRisk #DrugPricing #TariffRisk 🟢 Added 🟠 Removed https://d-risk.ai/SUPN/10-Q/2025-11-06

0 · Reply

kgpittm Nov. 5 at 6:01 PM

$SUPN Lots of profit taking going on here on a quarter where they took some one-time charges that impacted bottom line, but actually improved guidance for the year. Big yellow flag was actually that they are having supply issues due to the success of one of their newer products. They need to get that resolved quickly so that revenue growth can continue.

2 · Reply

DonCorleone77 Nov. 4 at 10:40 PM

$SUPN Supernus reports Q3 EPS (80c) vs. 69c last year -- Q3 revenue $192.1M, consensus $180.22M. -- Raises FY25 revenue view to $685M-$705M from $670M-$700M, consensus $702.59M. -- Raises FY25 adjusted operating earnings view to $125M-$145M from $105M-$135M.

0 · Reply

MrMaglue Nov. 4 at 9:03 PM

$SUPN https://ir.supernus.com/news-releases/news-release-details/supernus-announces-third-quarter-2025-financial-results

0 · Reply

Market Cap	2.53B
Revenue (ttm)	661.82M
Net Income (ttm)	73.87M
EPS (ttm)	N/A
PE Ratio	20.71
Forward PE	20.47
Profit Margin	11.16%
Debt to Equity Ratio	0.00

Volume	493,600
Avg Vol	880,618
Day's Range	N/A - N/A
Shares Out	57.34M
Stochastic %K	35%
Beta	0.71
Analysts	Strong Sell
Price Target	$60.50